Ketones

Kirkbride Center Expands Capacity to Respond to Opioid Crisis

Retrieved on: 
Tuesday, February 19, 2019
RTT, Chemistry, Drug rehabilitation, Morphinans, Organic chemistry, Opioid antagonists, Ketones, Cell signaling, Buprenorphine/naloxone, Methadone, Psychiatry, Institute of the Pennsylvania Hospital

PHILADELPHIA, Feb. 19, 2019 /PRNewswire/ --Kirkbride Center is one of the largest Medication Assisted Treatment (MAT) programs in Philadelphia.As a player on the front lines of opioid treatment, it offers three forms of Medication Assisted Treatment: Methadone, Suboxone and Vivitrol.

Key Points: 
  • PHILADELPHIA, Feb. 19, 2019 /PRNewswire/ --Kirkbride Center is one of the largest Medication Assisted Treatment (MAT) programs in Philadelphia.As a player on the front lines of opioid treatment, it offers three forms of Medication Assisted Treatment: Methadone, Suboxone and Vivitrol.
  • To effect an increase in MAT service capacity, Kirkbride has converted its 25-bed acute inpatient psychiatric program into a 32-bed short-term residential rehabilitation program.
  • The Kirkbride Center continuum has a total capacity for 270 beds.
  • Located in West Philadelphia, Kirkbride Center is pleased to be included in the 2.7 percent of rehabilitation facilities nationally that provides all three forms of Medication Assisted Treatment: Methadone,Suboxone and Vivitrol.

Mycotoxin Testing Market Worth $1,157 Million by 2023 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, February 19, 2019
Chemical compounds, Organic compounds, Mycotoxins, Chemistry, Ketones, Epoxides, Lactones, Food safety, Trichothecene, Foodborne illness, Vomitoxin, Nivalenol

Increase in instances of foodborne illness due to mycotoxin contamination, growth in the need for compliance with international trade mandates, and change in atmospheric conditions are some factors driving the growth in the mycotoxin testing market.

Key Points: 
  • Increase in instances of foodborne illness due to mycotoxin contamination, growth in the need for compliance with international trade mandates, and change in atmospheric conditions are some factors driving the growth in the mycotoxin testing market.
  • By type, the mycotoxin testing market is segmented into aflatoxin, ochratoxins, fumonisins, zearalenone, deoxynivalenol, trichothecenes, patulin, and others.
  • The mild to life-threatening disorders associated with DON, such as metabolic dysfunction, are creating an opportunity for the growth of the mycotoxin testing market.
  • The prevalence of Fusarium toxins due to the changing climatic conditions is also fueling the growth of the mycotoxin testing market.

Mycotoxin Testing Market Worth $1,157 Million by 2023 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, February 19, 2019
Chemical compounds, Organic compounds, Mycotoxins, Chemistry, Ketones, Epoxides, Lactones, Food safety, Trichothecene, Foodborne illness, Vomitoxin, Nivalenol

Increase in instances of foodborne illness due to mycotoxin contamination, growth in the need for compliance with international trade mandates, and change in atmospheric conditions are some factors driving the growth in the mycotoxin testing market.

Key Points: 
  • Increase in instances of foodborne illness due to mycotoxin contamination, growth in the need for compliance with international trade mandates, and change in atmospheric conditions are some factors driving the growth in the mycotoxin testing market.
  • By type, the mycotoxin testing market is segmented into aflatoxin, ochratoxins, fumonisins, zearalenone, deoxynivalenol, trichothecenes, patulin, and others.
  • The mild to life-threatening disorders associated with DON, such as metabolic dysfunction, are creating an opportunity for the growth of the mycotoxin testing market.
  • The prevalence of Fusarium toxins due to the changing climatic conditions is also fueling the growth of the mycotoxin testing market.

Global Male Hypogonadism API Manufacturers, Marketed and Phase III Drugs Landscape, 2019-2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 31, 2019
Health, Pharmaceutical, Endocrine system, Chemistry, Alcohols, Hypogonadism, Mammal reproductive system, Androstanes, Ketones, Medicine

The "Male Hypogonadism - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Male Hypogonadism - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Male Hypogonadism - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Male Hypogonadism .
  • Coverage of API manufacturers for Male Hypogonadism marketed products spanning across United States, Europe, China and India.
  • This report provides a comprehensive understanding of the emerging Phase III therapies for Male Hypogonadism which can turn out to be future prospective competitors for the marketed products.

Opioid-Induced Constipation - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 22, 2019
Health, Biotechnology, Pharmaceutical, Drugs, Morphine, Opioid, Opioid antagonists, Drug pipeline, Chemistry, Psychoactive drugs, Morphinans, Ketones

The "Opioid-Induced Constipation - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Opioid-Induced Constipation - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Opioid-Induced Constipation development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Opioid-Induced Constipation pipeline products by developmental stage, product type, molecule type, and administration route.

Testosterone Replacement Therapy In New Jersey Offered By Healthy Aging Medical Centers

Retrieved on: 
Friday, January 18, 2019
Endocrine system, Chemistry, Medicine, Testosterone, Alcohols, Androstanes, Ketones, Estrogens, Androgen replacement therapy, Hypogonadism, Hormone therapy

WEST ORANGE, N.J., Jan. 18, 2019 /PRNewswire/ -- Healthy Aging Medical Centers is pleased to announce it now offers Testosterone Replacement Therapy in New Jersey to help men and women get their testosterone levels back to optimal levels.

Key Points: 
  • WEST ORANGE, N.J., Jan. 18, 2019 /PRNewswire/ -- Healthy Aging Medical Centers is pleased to announce it now offers Testosterone Replacement Therapy in New Jersey to help men and women get their testosterone levels back to optimal levels.
  • Overall, Testosterone Replacement Therapy, as far as quality of life is concerned, has shown to have a tremendously positive impact.
  • Dr. Johanan Rand, MD , Founder and Medical Director of Healthy Aging Medical Centers, is board certified in Antiaging Medicine, Regenerative Medicine and Functional Medicine.
  • Healthy Aging Medical Centers in New Jersey offers simple methods of properly diagnosing men and women with low testosterone.

The Global Market for Testosterone Replacement Therapy (2019-2023): Leading Players are AbbVie, Bayer and Endo Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 10, 2019
Health, Pharmaceutical, Endocrine system, Chemistry, Testosterone, Medicine, Alcohols, Androstanes, Ketones, Estrogens, Androgen replacement therapy, Forecast period, Financial market

The "Global Testosterone Replacement Therapy Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Testosterone Replacement Therapy Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The testosterone replacement therapy market growth at a CAGR of more than (2%) during the forecast period.
  • The latest trend gaining momentum in the market is due to availability of such patient assistance programs, individuals are inclined toward buying these drugs, thereby increasing the growth of the market.
  • Further, the report states that one of the major factors hindering the growth of this market is the availability of generics in the market acts as a challenge of the growth of the market.

Global Opioid-Induced Constipation Market 2018-2022: Introduction of Separate Diagnostic Guidelines for Idiopathic or Functional Constipation and OIC

Retrieved on: 
Thursday, January 10, 2019
Medicine, Chemistry, RTT, Gastroenterology, Morphine, Opioid, Ketones, Opioid antagonists, Alcohols, Constipation, Migraine, Methylnaltrexone

The "Global Opioid-Induced Constipation Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Opioid-Induced Constipation Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
  • The opioid-induced constipation market will register a CAGR of more than 32% by 2022.
  • Rise in incidence of chronic diseases such as arthritis, back pain, and migraine is likely to drive growth in the market.
  • The use of laxatives for OIC is a major challenge that is reducing sales of approved drugs meant for the treatment of OIC.

Positive Results From Human PK Study Assessing Orexo's New Intranasal Naloxone Formulations for Opioid Overdose Reversal

Retrieved on: 
Monday, January 7, 2019
RTT, Chemistry, Organic chemistry, Morphinans, Cell signaling, Opioid antagonists, Opioids, Ketones, Naloxone, Opioid use disorder, Opioid, Hypoventilation

Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces positive results from the human pharmacokinetic (PK) study OX124-001 in 20 healthy volunteers, assessing Orexo's novel naloxone nasal spray formulations intended for opioid overdose reversal.

Key Points: 
  • Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces positive results from the human pharmacokinetic (PK) study OX124-001 in 20 healthy volunteers, assessing Orexo's novel naloxone nasal spray formulations intended for opioid overdose reversal.
  • The study was a cross-over, comparative, bioavailability study comparing four development formulations of OX124 to Narcan Nasal Spray 4mg, the current market-leading naloxone rescue medication in the US.
  • Naloxone is a full opioid receptor antagonist which reverses the effects of opioid agonists, including the life threatening respiratory depressant effects occurring in an opioid overdose.
  • OX124-001 was a randomized, open label study designed to evaluate the bioavailability of nasally administered naloxone formulations in healthy subjects.

Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference

Retrieved on: 
Friday, December 21, 2018
Medicine, Hepatitis, Chemistry, Ketones, Alcohols, Androstanes, Estrogens, Bioidentical hormone replacement therapy, Non-alcoholic fatty liver disease, Testosterone, Steatohepatitis

"We look forward to sharing the results from our clinical trials with LPCN 1144 as part of the 2019 NASH-TAG Conference," Dr. Patel further stated.

Key Points: 
  • "We look forward to sharing the results from our clinical trials with LPCN 1144 as part of the 2019 NASH-TAG Conference," Dr. Patel further stated.
  • Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies.
  • Lipocine's clinical development pipeline includes four development programs TLANDO, LPCN 1144, LPCN 1111 and LPCN 1107.
  • LPCN 1144, an oral prodrug of bioidentical testosterone, is being developed as a treatment of non-alcoholic steatohepatitis ("NASH") and is currently being studied in two proof-of-concept clinical studies.